San Francisco-based Vial has dosed the first asthma patient in a Phase Ib trial of its IL-13/TSLP bispecific antibody, which is engineered for potential twice-yearly dosing. Interim results are expected in the first half of 2027.
The antibody combines blockade of TSLP, an upstream driver of Type 2 inflammation, with IL-13, which mediates downstream inflammatory effects. Vial aims to combine this dual action with an extended half-life to provide durable disease control.
The randomised, double-blind, placebo-controlled trial will assess safety and tolerability in adults with mild-to-moderate asthma. Other measures include pharmacokinetics, exhaled nitric oxide (FeNO), lung function (FEV1) and inflammatory biomarkers. Results will guide dose and dosing-interval selection.
The study follows five single ascending dose cohorts in healthy volunteers, who received intravenous doses of 15 mg to 800 mg. Vial reported that the antibody was generally well tolerated and showed pharmacokinetics that could support extended dosing intervals, although twice-yearly disease control has yet to be demonstrated in patients.